A Bayer drug that hits two central nervous system targets to deal with moderate-to-severe menopause signs has FDA approvalintroducing a brand new non-hormonal therapeutic choice which will have a bonus over an Astellas Pharma product that has a two-year head begin on this market.
The Bayer drug, elinzanetant, is a small molecule formulated as a comfortable gel capsule taken as soon as day by day earlier than bedtime. Bayer will commercialize this new menopause drug beneath the model identify Lynkuet.
Hormone therapies are an ordinary remedy for menopause’s vasomotor signs, equivalent to scorching flashes and night time sweats. However such therapies can increase the danger of cardiovascular issues, so ladies who’ve coronary heart points want non-hormonal choices. Lynkuet is a small molecule designed to inhibit two targets, the NK1 and NK3 receptors, each of which play roles in regulating physiological processes equivalent to physique temperature. The twin-targeting method of Lynkuet differentiates it from Astellas’s Veozah, an NK3 receptor-blocking drug that gained its FDA approval in 2023.
Lynkuet may even have a security benefit over the Astellas menopause drug. Final fall, the FDA issued a security communication about Veozah after a affected person who had been taking the once-daily capsule for about 40 days developed indicators and signs of liver damage. Final December, the FDA added a black field warning to the product’s label flagging these dangers.
In January interview, Astellas Chief Medical Officer Tadaaki Taniguchi mentioned liver toxicity is a recognized threat that was recognized in scientific testing. He added that this threat is uncommon and “we imagine that the danger/profit stability is absolutely optimistic.” For the 2024 fiscal yr, Astellas reported 33.8 billion Japanese yen (about $220 million) in gross sales. For the 2025 fiscal yr, Astellas initiatives 50 billion yen (about $330 million) in gross sales.
Lynkuet was initially developed by KaNDy Therapeutics. When Bayer acquired the ladies’s well being firm in 2020, the drug was prepared for Section 3 testing. Lynkuet’s efficacy was evaluated in two placebo-controlled Section 3 research. Outcomes confirmed the drug met the principle objectives of lowering the frequency and severity of scorching flashes measured at weeks 4 and 12.
A 3rd Section 3 examine evaluated the drug for one yr with a most important purpose of assessing security. Unwanted side effects reported within the research included headache, fatigue, dizziness, and drowsiness. Lynkuet’s label has no black field warning, although the prescribing info directs clinicians to carry out bloodwork to check for liver perform and damage earlier than a affected person begins taking the medicine, after which a follow-up take a look at three month afterward.
“Scorching flashes, notably when extreme, can have an effect on ladies’s day by day lives and this approval supplies healthcare suppliers with a brand new remedy choice that can be utilized first line for reasonable to extreme scorching flashes attributable to menopause,” Dr. JoAnn Pinkerton, professor and director of midlife well being at UVA Well being and lead investigator within the drug’s OASIS 2 Section 3 scientific trial, mentioned in a ready assertion.
Within the Lynkuet approval announcement Friday, Bayer mentioned it expects the brand new menopause drug will develop into obtainable to U.S. sufferers in November. It’s already authorised in Australia, Canada, the UK, and Switzerland. Lynkuet continues to be beneath regulatory evaluation within the European Union and different international markets.
Photograph: Krisztian Bocsi/Bloomberg, by way of Getty Photos
